

AMENDMENTS TO THE CLAIMS

Please enter the following amendments to the claims:

1-24. **(Cancelled)**

25. **(New)** A lipophilic formulation for nasal application, comprising:

- a) at least one sexual hormone drug;
- b) at least one lipophilic or partly lipophilic carrier comprising an oil; and
- c) a compound or a mixture of compounds having surface tension decreasing

activity,

wherein the at least one sexual hormone drug is maintained at a serum level greater than baseline for at least six hours after a single application of the formulation.

26. **(New)** The formulation according to claim 25, wherein the oil is a vegetable oil.

27. **(New)** The formulation according to claim 26, wherein the vegetable oil is castor oil.

28. **(New)** The formulation according to claim 25, wherein the oil is in an amount between 30% and 98% by weight of the formulation.

29. **(New)** The formulation according to claim 28, wherein the oil is in an amount between 60% and 98% by weight of the formulation.

30. **(New)** The formulation according to claim 29, wherein the oil is in an amount of around 90% by weight of the formulation.

31. **(New)** The formulation according to claim 25, wherein component (c) comprises:

(i) at least one surfactant selected from the group consisting of: lecithin, fatty acid ester of polyvalent alcohols, fatty acid ester of sorbitanes, fatty acid ester of polyoxyethylensorbitans, fatty acid ester of polyoxyethylene, fatty acid ester of sucrose, and fatty acid ester of polyglycerol; or

(ii) at least one humectant selected from the group consisting of: sorbitol, glycerine, polyethylene glycol, and macrogol glycerol fatty acid ester; or

(iii) a mixture thereof.

32. **(New)** The formulation according to claim 31, wherein component (c) comprises an oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides.

33. (New) The formulation according to claim 25, wherein component (c) is in an amount between 1% and 20%.

34. (New) The formulation according to claim 33, wherein component (c) is in an amount between 1% and 5%.

35. (New) The formulation according to claim 25, further comprising a viscosity regulating agent.

36. (New) The formulation according to claim 35, wherein the viscosity regulating agent comprises a thickener or gelling agent selected from the group consisting of: cellulose and cellulose derivatives, polysaccharides, carbomers, polyvinyl alcohol, povidone, colloidal silicon dioxide, cetyl alcohols, stearic acid, beeswax, petrolatum, triglycerides, lanolin, and a mixture thereof.

37. (New) The formulation according to claim 36, wherein the viscosity regulating agent is colloidal silicon dioxide.

38. (New) The formulation according to claim 35, wherein the viscosity regulating agent is in an amount between 0.5% and 10% by weight of the formulation.

39. (New) The formulation according to claim 38, wherein the viscosity regulating agent is in an amount between 1% and 3% by weight of the formulation.

40. (New) The formulation according to claim 25, wherein the at least one sexual hormone drug is in an amount between 0.5% and 6% by weight of the formulation.

41. (New) The formulation according to claim 40, wherein the at least one sexual hormone drug is in an amount between 0.5% to 2% by weight of the formulation.

42. (New) The formulation according to claim 25, wherein the at least one sexual hormone drug is testosterone.

43. (New) The formulation according to claim 25, wherein the at least one sexual hormone drug is maintained at a serum level greater than baseline for at least ten hours after a single application of the formulation.

44. (New) The formulation according to claim 25, wherein the formulation is free of water.